Display Settings:

Format

Send to:

Choose Destination

Results: 2

1.

Omeprazole response

Omeprazole blocks the secretion of gastric acid and belongs to the drug class of proton pump inhibitors. It is used to treat gastroesophageal reflux disease (GERD), gastric ulcers and duodenal ulcers. It is also used to eradicate H. pylori infection and maintain healing in erosive esophagitis. CYP2C19 is the principal enzyme that metabolizes omeprazole to inactive metabolites. In individuals who have reduced or absent CYP2C19 enzyme activity, the recommended doses of omeprazole may lead to higher exposure to the drug and increased clinical efficacy. In contrast, individuals with increased CYP2C19 activity ("ultrarapid metabolizers") may be exposed to lower levels of omeprazole. Currently, the FDA does not require genetic testing of CYP2C19 prior to treatment with omeprazole. However, the Dutch Pharmacogenetics Working Group recommends dose alterations based on CYP2C19 genotype. For the eradication of H. pylori in ultrarapid metabolizers, they recommend a 100-200% increase of omeprazole dose. The same dose increase should also be considered for the treatment of other conditions. [from Medical Genetics Summaries]

MedGen UID:
472581
Concept ID:
CN158357
Sign or Symptom
2.

Esomeprazole response

Esomeprazole blocks the secretion of gastric acid and belongs to the drug class of proton pump inhibitors. It is used to treat gastroesophageal reflux disease (GERD), to eradicate H. pylori infection, and to reduce the risk of gastric ulcers associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs). Esomeprazole is metabolized by the enzymes CYP3A4 and CYP2C19. In individuals who have reduced or absent CYP2C19 enzyme activity, the recommended doses of esomeprazole may lead to higher exposure to the drug and increased clinical efficacy. In contrast, individuals with increased CYP2C19 activity ("ultrarapid metabolizers") may be exposed to lower levels of esomeprazole. Currently, the FDA does not require genetic testing of CYP2C19 prior to treatment with esomeprazole. However, the Dutch Pharmacogenetics Working Group recommends dose alterations based on CYP2C19 genotype. For the eradication of H. pylori in ultrarapid metabolizers, they recommend a 50-100% increase of esomeprazole dose. The same dose increase should also be considered for the treatment of other conditions. [from Medical Genetics Summaries]

MedGen UID:
450454
Concept ID:
CN077982
Sign or Symptom

Supplemental Content

Find related data

Recent activity